Evaluation of the effect of oral eplerenone in the management of Acute Central Serous Chorioretinopathy

Phase 3

Recruiting

• Conditions: Acute Central Serous Chorioretinopathy.; Separation of retinal layers; H35.7

• Registration Number: IRCT20220423054621N1
• Lead Sponsor: Bagheiat-allah University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 22 July 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Diagnosis of acute central serous chorioretinopathy before twelve weeks
Diagnosis of acute central serous chorioretinopathy for the first time

Exclusion Criteria

Chronic CSCR (duration of visual symptoms more than 12 weeks)
Recurrent CSCR (patients with a history of one or more previous CSCR attacks)
Choroidal neovascularization (CNV) detected by FA, ??ICGA, or OCT angiography (OCT-A)
Any treatment for retinal disease (including intravitreal injections, photodynamic therapy, laser photocoagulation, vitrectomy)
History of other retinal disorders (including age-related macular degeneration, choroidal neovascularization, diabetic retinopathy, uveitis, or pathological myopia)
The presence of any other systemic disease for which eplerenone is contraindicated (such as severe renal, cardiac or hepatic failure, pregnancy, baseline serum potassium more than 0.5 mEq/L
simultaneous administration of potassium-sparing diuretics, potassium supplements, inhibitors angiotensin converting enzyme or angiotensin receptor blockers)

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Best corrected visual acuity (BCVA). Timepoint: At the beginning of the study, one month, two months and three months later. Method of measurement: Tumbling E” eye chart.;Central Macular Thickness (CMT). Timepoint: At the beginning of the study, one month, two months and three months later. Method of measurement: Use of SD-OCT device.